source
- Neumora Therapeutics halts lead depression drug after two more Phase 3 failures, plans 35% staff cutsNeumora Therapeutics announced that its lead depression candidate will be discontinued after it did not meet primary endpoints in two additional Phase 3 trials. The company said the data were consi…
- Sanofi’s Tzield approved amid review dispute as Bicillin shortage hampers syphilis treatmentAn Arizona woman pregnant with syphilis could not receive timely treatment because of a worsening shortage of Bicillin, the injectable penicillin made by Pfizer. The shortage has raised concerns ab…